Efficacy of rituximab in gastric diffuse large B cell lymphoma patients

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 20

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

382

HTML

3141

Figures (1-1)

219

Tables (1-4)

208

Sum=3950

May 28, 2010 (publication date) through Dec 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. May 28, 2010; 16(20): 2526-2530
Published online May 28, 2010. doi: 10.3748/wjg.v16.i20.2526

Table 3 Treatment response

Chemo-immunotherapy treatment
No. of patients
CHOP-like	30
CHOP-like and rituximab	30
Second or other lines	7.50%
No. of cycles
Median	6 (3-24)
mean	8.3 (3-24)
Results
Median follow-up	77 mo
CHOP-like	CR = 76.6%, DFS at 5 yr = 73.3%, OS = 63.3%
CHOP-like and rituximab	CR = 100%, DFS at 5 yr = 100%, OS = 100%

CHOP: Cyclophosphamide, doxorubicin, vincristine and prednisone; CR: Complete response; DFS: Disease-free survival; OS: Overall survival.

Citation: Leopardo D, Lorenzo GD, Renzo AD, Federico P, Luponio S, Buonerba C, Matano E, Merola G, Imbimbo M, Montesarchio E, Rea A, Merola MC, Placido SD, Palmieri G. Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. World J Gastroenterol 2010; 16(20): 2526-2530
URL: https://www.wjgnet.com/1007-9327/full/v16/i20/2526.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i20.2526